KCNH4 and melanoma: Four patients developed IgM anti-GD3 but no patient developed IgG anti-GD3, despite the use of the immunization booster.70 Unfortunately, this association showed no impact on immunization.70 The association of Bec2-KLH with Bacille Calmette-Guerin (BCG) therapy showed promising results in inducing anti-GD3 antibodies for 3 out of 14 patients with melanoma after complete resection and at high risk of relapse in a phase 1 clinical trial.